The page you are requesting does not exist. You can start your search here!
Sort by
Refine Your Search
-
manufacturing procedures and the requirement for lymphodepleting chemotherapy, which together limit patient access. Here, we propose an in vivo engineering strategy based on targeted lipid nanoparticles (tLNPs
-
genetic screens in Primary and cell line models of T-cell lymphomas and characterize their oncogenic dependencies, and functionally validate them using CRISPR-based genetic perturbation approaches. Through
Searches related to model driven engineering
Enter an email to receive alerts for model-driven-engineering positions